Curis (CRIS) Announces Publication of Encouraging CUDC-907 Phase 1 Data
Tweet Send to a Friend
Curis, Inc. (Nasdaq: CRIS) announced the publication of results from the dose escalation part of the Phase 1 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
